# Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria

> **NCT00616304** · PHASE2 · SUSPENDED · sponsor: **Menzies School of Health Research** · enrollment: 8 (actual)

## Conditions studied

- Severe Falciparum Malaria

## Interventions

- **DRUG:** L-arginine hydrochloride
- **OTHER:** Normal saline

## Key facts

- **NCT ID:** NCT00616304
- **Lead sponsor:** Menzies School of Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2008-02
- **Primary completion:** 2009-03
- **Final completion:** —
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Local circumstances \& difficulties in site access has prevented continuation
- **Last updated:** 2024-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616304, "Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00616304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*